4967 KOBAYASHI PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4967

TSE Prime

KOBAYASHI PHARMACEUTICAL CO.,LTD.

5,251

JPY

-2

(-0.04%)

Dec 5, 12:53 pm JST

33.84

USD

Dec 4, 10:53 pm EST

Result

PTS

outside of trading hours

5,261.8

Dec 5, 12:42 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	155,252	26,065	28,015	19,715	252.4	83	Feb 4, 2022	J-GAAP
Dec, 2022	166,258	26,669	28,281	20,022	259.6	90	Feb 14, 2023	J-GAAP
Dec, 2023	173,455	25,780	27,330	20,338	268.2	101	Feb 9, 2024	J-GAAP
Dec, 2024	165,600	24,860	26,861	10,067	135.4	102	Feb 10, 2025	J-GAAP
Dec, 2025 Guidance	171,000	14,000	15,300	10,500	141.3	104	Feb 10, 2025	J-GAAP
YoY	+3.3%	-43.7%	-43.0%	+4.3%	+4.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Jan 31, 2020	165,000	26,400	28,000	20,000	75	J-GAAP
	Jul 30, 2020	154,000	25,900	27,600	19,200	75	J-GAAP
Results	Feb 1, 2021	150,514	25,943	27,726	19,205	77	J-GAAP
Dec, 2021	Feb 1, 2021	Available in future release
	Jul 29, 2021
Results	Feb 4, 2022
Dec, 2022	Feb 4, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
	Aug 8, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
	May 10, 2024
	Aug 8, 2024
	Nov 8, 2024
Results	Feb 10, 2025
Dec, 2025	Feb 10, 2025	171,000	14,000	15,300	10,500	104	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	185,001	+2.4	Available in future release
Mar, 2002	204,647	+10.6
Mar, 2003	210,922	+3.1
Mar, 2004	211,670	+0.4
Mar, 2005	215,708	+1.9
Mar, 2006	246,852	+14.4
Mar, 2007	257,022	+4.1
Mar, 2008	228,826	-11.0
Mar, 2009	125,693	-45.1
Mar, 2010	129,184	+2.8
Mar, 2011	130,824	+1.3
Mar, 2012	131,166	+0.3
Mar, 2013	121,532	-7.3
Mar, 2014	127,293	+4.7
Mar, 2015	128,344	+0.8
Mar, 2016	137,211	+6.9
Dec, 2016 Changed	120,051	－
Dec, 2017	156,761	+30.6
Dec, 2018	167,479	+6.8
Dec, 2019	158,340	-5.5
Dec, 2020	150,514	-4.9
Dec, 2021	155,252	+3.1
Dec, 2022	166,258	+7.1
Dec, 2023	173,455	+4.3
Dec, 2024	165,600	-4.5
Dec, 2025 Guidance	171,000	+3.3	14,000	-43.7	15,300	-43.0	141.3	+4.4

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	173,455	25,780	14.9	10.12	7.77	0.66	268.2
Dec, 2024	165,600	24,860	15.0	4.83	3.78	0.62	135.4
Dec, 2025 Guidance	171,000	14,000	8.19	4.97	4.02	0.65	141.3

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	257,022	26,669	28,281	20,338	268.2
Fiscal Year	Mar, 2007	Dec, 2022	Dec, 2022	Dec, 2023	Dec, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	94,994	16,801	17,377	12,322	159.8	52	Feb 14, 2023	J-GAAP
Jul - Dec, 2023	99,830	15,374	16,156	12,474	164.5	58	Feb 9, 2024	J-GAAP
Jul - Dec, 2024	92,464	15,389	16,427	8,631	116.1	59	Feb 10, 2025	J-GAAP
Jul - Dec, 2025 Guidance	101,982	7,352	8,055	7,333	98.7	60	Aug 5, 2025	J-GAAP
YoY	+10.3%	-52.2%	-51.0%	-15.0%	-15.0%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	26,669	17,602	31,914	-14,312	-20,759	79,480	31.07	J-GAAP
Dec, 2023	25,780	-1,216	18,360	-19,576	-19,463	59,690	22.32	J-GAAP
Dec, 2024	24,860	-7,169	11,246	-18,415	-7,768	45,973	17.32	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	119,115	19,387	20,837	15,498	203.6	76.2	Nov 7, 2023	J-GAAP
Jan - Sep, 2024	114,459	16,976	17,921	5,344	71.9	66.7	Nov 8, 2024	J-GAAP
Jan - Sep, 2025	112,038	11,495	12,930	6,809	91.6	84.5	Nov 11, 2025	J-GAAP
YoY	-2.1%	-32.3%	-27.9%	+27.4%	+27.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	54,340	6,393	6,493	4,840	63.8	11.8	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	36,485	5,028	5,461	976	13.1	13.8	May 10, 2024	J-GAAP
Apr - Jun, 2024	36,651	4,443	4,973	460	6.2	12.1	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	41,323	7,505	7,487	3,908	52.6	18.2	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	51,141	7,884	8,940	4,723	63.5	15.4	Feb 10, 2025	J-GAAP
Jan - Mar, 2025	32,607	2,535	2,401	1,624	21.9	7.8	May 9, 2025	J-GAAP
Apr - Jun, 2025	36,411	4,113	4,844	1,543	20.8	11.3	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	43,020	4,847	5,685	3,642	49.0	11.3	Nov 11, 2025	J-GAAP
YoY	+4.1%	-35.4%	-24.1%	-6.8%	-6.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	45,465	-3.5	Available in future release
Jan - Mar, 2021	30,269	-5.1
Apr - Jun, 2021	36,783	+7.3
Jul - Sep, 2021	40,606	+4.5
Oct - Dec, 2021	47,594	+4.7
Jan - Mar, 2022	32,646	+7.9
Apr - Jun, 2022	38,618	+5.0
Jul - Sep, 2022	43,015	+5.9
Oct - Dec, 2022	51,979	+9.2
Jan - Mar, 2023	33,467	+2.5
Apr - Jun, 2023	40,158	+4.0
Jul - Sep, 2023	45,490	+5.8
Oct - Dec, 2023	54,340	+4.5
Jan - Mar, 2024	36,485	+9.0
Apr - Jun, 2024	36,651	-8.7
Jul - Sep, 2024	41,323	-9.2
Oct - Dec, 2024	51,141	-5.9
Jan - Mar, 2025	32,607	-10.6
Apr - Jun, 2025	36,411	-0.7
Jul - Sep, 2025	43,020	+4.1	4,847	-35.4	5,685	-24.1	49.0	-6.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	71,727	9,295	10,013	7,634	100.3
Fiscal Year	Dec, 2007	Sep, 2020	Sep, 2020	Sep, 2023	Sep, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Announce	Accounting Standards
Dec, 2022	2,600.04	77.3	255,827	197,639	194,285	Feb 14, 2023	J-GAAP
Dec, 2023	2,749.17	76.4	267,473	204,370	205,681	Feb 9, 2024	J-GAAP
Dec, 2024	2,862.28	80.2	265,368	212,778	208,240	Feb 10, 2025	J-GAAP
Jan - Sep, 2025	ー	80.8	261,453	211,268	207,393	Nov 11, 2025	J-GAAP

KOBAYASHI PHARMACEUTICAL CO.,LTD.(4967) Financial Results